RETINAL ANGIOMATOUS PROLIFERATION: Natural History and Progression of Visual Loss
The DOI matches its Crossref record, with a small difference in title or year; 23 of the 23 references it cites were found in a registry or an index.
Abstract
PURPOSE: To investigate the natural history and visual outcome in eyes with untreated retinal angiomatous proliferation, a neovascular form of age-related macular degeneration. METHODS: Fourteen consecutive white patients (11 women, 78%; mean age, 74 years) with 16 eyes affected by retinal angiomatous proliferation were prospectively followed-up without treatment by means of complete ophthalmologic examinations at regular intervals, including best-corrected visual acuity and dynamic fluorescein and indocyanine green angiography using a scanning laser ophthalmoscope. RESULTS: The patients were observed for a mean of 20 months (range, 6-44 months). Mean visual acuity in the eyes with retinal angiomatous proliferation was 0.48 at the initial examination, decreased to 0.23 after 6 months, and was 0.19 at the final examination, with a mean decrease of 6 lines from baseline. In 13 eyes (81%), visual acuity deteriorated by 2 Early Treatment Diabetic Retinopathy Study lines or worse by the time of the 6-month examination, and 31% of the patients had experienced severe loss of vision; the remaining 3 eyes (19%) showed a relatively stable clinical course and visual acuity. By the time of the final examination, visual acuity had decreased to 0.1 or worse in 11 eyes (69%), and 5 of the 14 patients (36%) were legally blind. At the final examination, 10 eyes (62%) showed a subretinal fibrosis and 9 (56%) showed a retinal choroidal anastomosis. CONCLUSION: Retinal angiomatous proliferation is a distinct form of neovascular age-related macular degeneration with high vasogenic potential, having its own clinical course and visual prognosis. The poor visual outcome is because of the exudative nature of the retinal angiomatous proliferation, and progression to poor vision is common and rapid (within 3 months in faster cases, and within 1 year in slower cases). The treatment options for this type of neovascular lesion should be planned bearing in mind its unfavorable natural history.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A relatively small study that followed the natural history of RAP lesions for a mean duration of 20 months found subretinal fibrosis on FA and red-free photographs in 10 of 16 eyes (62%),38”
From Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials (2014) · cites this paper as [38]
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Fung, A. E., Lalwani, G. A., Rosenfeld, P. J., Dubovy, S. R., Michels, S., Feuer, W. J., Puliafito, C. A., Davis, J. L., Flynn, H. W., & Esquiabro, M. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.01.028 · Cited by 972
(2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)00967-9 · Cited by 814
Bressler, N. M. (2002) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)01237-5 · Cited by 666
RETINAL ANGIOMATOUS PROLIFERATION IN AGE–RELATED MACULAR DEGENERATION
Yannuzzi, L. A., Negrão, S., IIDA, T., Carvalho, C., Rodriguez-Coleman, H., Slakter, J., Freund, K. B., Sorenson, J., Orlock, D., & Borodoker, N. (2012) · Retina · doi:10.1097/iae.0b013e31823f9b3b · Cited by 660
RETINAL ANGIOMATOUS PROLIFERATION IN AGE-RELATED MACULAR DEGENERATION
YANNUZZI, L. A., NEGRÃO, S., IIDA, T., CARVALHO, C., RODRIGUEZ-COLEMAN, H., SLAKTER, J., FREUND, K. B., SORENSON, J., ORLOCK, D., & BORODOKER, N. (2001) · Retina · doi:10.1097/00006982-200110000-00003 · Cited by 659
The Natural History and Prognosis of Neovascular Age-Related Macular Degeneration
Wong, T., Chakravarthy, U., Klein, R., Mitchell, P., Zlateva, G., Buggage, R., Fahrbach, K., Probst, C., & Sledge, I. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.03.008 · Cited by 601
TYPE 3 NEOVASCULARIZATION: The Expanded Spectrum of Retinal Angiomatous Proliferation
FREUND, K. B., -VAN HO, I., BARBAZETTO, I. A., KOIZUMI, H., LAUD, K., FERRARA, D., MATSUMOTO, Y., SORENSON, J. A., & YANNUZZI, L. (2008) · Retina · doi:10.1097/iae.0b013e3181669504 · Cited by 295
Deep Retinal Vascular Anomalous Complexes in Advanced Age-related Macular Degeneration
Hartnett, M. E., Weiter, J. J., Staurenghi, G., & Elsner, A. E. (1996) · Ophthalmology · doi:10.1016/s0161-6420(96)30389-8 · Cited by 216
Self-citation
Cited by
Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials
Daniel, E., Toth, C. A., Grunwald, J. E., Jaffe, G. J., Martin, D. F., Fine, S. L., Huang, J., Ying, G.-S., Hagstrom, S. A., Winter, K., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.019 · Cited by 335
Little, K., Llorián-Salvador, M., Tang, M., Du, X., Marry, S., Chen, M., & Xu, H. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-02033-7 · Cited by 149
Wang, J., Jiang, J., Zhang, Y.-Y., Qian, Y., Zhang, J., & Wang, Z. L. (2019) · Biomedical Optics Express · doi:10.1364/boe.10.001532 · Cited by 159
Joussen, A. M., Ryan, S. J., Kirchhof, B., & Gardner, T. W. (2007) · Springer eBooks · doi:10.1007/978-3-540-29542-6 · Cited by 130
Little, K., Jacey, H., Yang, N., Chen, M., & Xu, H. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.11.029 · Cited by 131
Daniel, E., Shaffer, J., Ying, G., Grunwald, J. E., Martín, D., Jaffe, G. J., & Maguire, M. G. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.10.034 · Cited by 110
Retinal angiomatous proliferation
Tsai, A. S. H., Cheung, N., Gan, A. T. L., Jaffe, G. J., Sivaprasad, S., Wong, T. Y., & Cheung, C. M. G. (2017) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2017.01.008 · Cited by 82
Mathis, T., Holz, F. G., Sivaprasad, S., Yoon, Y. H., Eter, N., Chen, L.-J., Koh, A. C., de Souza, E. C., & Staurenghi, G. (2022) · Eye · doi:10.1038/s41433-022-02231-y · Cited by 66
“[29] reported that 69% of eyes with RAP (type 3) MNV had VA of 20/200 or less, 36% of patients were legally blind at 1 year, and the mean decrease in VA was around six lines at 1 year.”
BackgroundSelf-citationSawa, M., Ueno, C., Gomi, F., & Nishida, K. (2013) · Retina · doi:10.1097/01.iae.0000434566.57189.37 · Cited by 56
“The natural course of RAP is well associated with a poor visual prognosis.(11) In light of this, the study of Gross et al(3) alerted us to the importance of following patients with unilateral RAP more closely than other AMD manifestations.”
BackgroundCol4a1 mutations cause progressive retinal neovascular defects and retinopathy
Alavi, M. V., Mao, M., Pawlikowski, B. T., Kvezereli, M., Duncan, J. L., Libby, R. T., John, S. W. M., & Gould, D. B. (2016) · Scientific Reports · doi:10.1038/srep18602 · Cited by 57
Hemeida, T. S., Keane, P. A., Dustin, L., Sadda, S. R., & Fawzi, A. A. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2009.167627 · Cited by 56
“In 13 eyes (81%), VA deteriorated by two or more lines at 6 months.(25) To our knowledge, this is the longest follow-up study for RAP lesions treated with anti-VEGF monotherapy.”
BackgroundKim, J. H., Chang, Y. S., Kim, J. W., Lee, T. G., & Kim, C. G. (2015) · Retina · doi:10.1097/iae.0000000000000633 · Cited by 51
“The natural history of RAP is generally poor.(18) Recently, Hogg et al(19) evaluated clinical characteristics of reticular pseudodrusen in the fellow eye of patients with unilateral neovascular AMD.”
BackgroundHan, J., Choi, S., Park, J. I., Hwang, J. S., Han, J. M., Lee, H. J., Ko, J., Yoon, J., & Hwang, D. D.-J. (2022) · Scientific Reports · doi:10.1038/s41598-022-05903-7 · Cited by 52
Combined Intravitreal Ranibizumab and Photodynamic Therapy for Retinal Angiomatous Proliferation
Lee, M. Y., Kim, K. S., & Lee, W. K. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.01.028 · Cited by 47
dell’Omo, R., Cassetta, M., dell’Omo, E., di Salvatore, A., Hughes, J. M., Aceto, F., Porcellini, A., & Costagliola, C. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.06.001 · Cited by 44
Geographic Atrophy and Activity of Neovascularization in Retinal Angiomatous Proliferation
Baek, J., Lee, J. H., Kim, J. Y., Kim, N. H., & Lee, W. K. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-18837 · Cited by 43
Gharbiya, M., Parisi, F., Cruciani, F., Pantaleoni, F. B., Pranno, F., & Abdolrahimzadeh, S. (2013) · Retina · doi:10.1097/iae.0b013e3182979e62 · Cited by 40
“In our series, the mean number of treatment over 2 years was similar to that of the PrONTO Study (8.8 ± 4.4 vs. 9.9 ± 5.3 in the PrONTO Study), pointing out, once again, that the response of RAP to anti-VEGF agents may be similar to that of other variants of neovascular AMD.”
BackgroundInfluentialCho, H. J., Lee, T. G., Han, S. Y., Kim, H. S., Kim, J. H., Han, J. I., Lew, Y. J., & Kim, J. W. (2015) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-015-2993-3 · Cited by 38
Characterization of a Spontaneous Retinal Neovascular Mouse Model
Hasegawa, E., Sweigard, H., Husain, D., Olivares, A. M., Chang, B., Smith, K. E., Birsner, A. E., D’Amato, R. J., Michaud, N. A., Han, Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0106507 · Cited by 38
“AMD, affects 1 in 3 individuals over age 65, occurs in two forms: exudative (‘‘wet’’) and nonexudative (‘‘dry’’).”
BackgroundInfluentialRetinal angiomatous proliferation or retinal anastomosis to the lesion
Scott, A. W., & Bressler, S. B. (2009) · Eye · doi:10.1038/eye.2009.311 · Cited by 37
Shin, J. Y., & Yu, H. G. (2014) · Retina · doi:10.1097/iae.0000000000000225 · Cited by 37
Intravitreal bevacizumab versus ranibizumab for the treatment of retinal angiomatous proliferation
Parodi, M. B., Iacono, P., Menchini, F., Sheth, S., Polini, G., Pittino, R., & Bandello, F. M. (2011) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2011.02265.x · Cited by 35
“1 or worse in 69% of patients at the final examination, with a six-line visual acuity loss registered in 30% of cases during the first 6 months (Viola et al. 2009).”
BackgroundInfluentialNguyen, V., Barthelmes, D., & Gillies, M. C. (2021) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13949 · Cited by 34
Hwang, D. D.-J., Choi, S., Ko, J., Yoon, J., Park, J. I., Hwang, J. S., Han, J. M., Lee, H. J., Sohn, J., Park, K. H., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-88543-7 · Cited by 33
RETINAL ANGIOMATOUS PROLIFERATION DIAGNOSIS: A Multiimaging Approach
Ravera, V., Bottoni, F. G., Giani, A., Cigada, M., & Staurenghi, G. (2016) · Retina · doi:10.1097/iae.0000000000001152 · Cited by 31
“Advances in fundus imaging and histopathological correlations have validated the original assumption of Hartnett et al and the importance of distinguishing RAP from Type 1 or Type 2 neovascularization in AMD.(8,9) Freund et al(10) have also proposed the term “type 3 neovascularization” for this entity.”
BackgroundMethodSelf-citationRouvas, A. A., Chatziralli, I. P., Theodossiadis, P. G., Moschos, M. M., Kotsolis, A. I., & Ladas, I. D. (2012) · Retina · doi:10.1097/iae.0b013e318235d8ce · Cited by 30
“” There is a controversy about which is the most appropriate treatment of RAP, although it is generally considered that RAP has a poor prognosis because it typically progresses to severe stages ending in a disciform scar.(12) Before the introduction of anti–vascular endothelial growth factor (anti-VEGF) agents, there…”
BackgroundCampa, C., Harding, S. P., Pearce, I. A., Beare, N. A. V., Briggs, M. C., & Heimann, H. (2010) · Eye · doi:10.1038/eye.2010.88 · Cited by 30
Bhavsar, K. V., Jia, Y., Wang, J., Patel, R. C., Lauer, A. K., Huang, D., & Bailey, S. T. (2017) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2017.10.001 · Cited by 28
Hata, M., Yamashiro, K., Oishi, A., Ooto, S., Tamura, H., Miyata, M., Ueda‐Arakawa, N., Kuroda, Y., Takahashi, A., Tsujikawa, A., et al. (2017) · Retina · doi:10.1097/iae.0000000000001457 · Cited by 27
Combined Intravitreal Ranibizumab and Photodynamic Therapy for Retinal Angiomatous Proliferation
Saito, M., Iida, T., & Kano, M. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.08.038 · Cited by 27
Environmental and genetic risk factors for retinal angiomatous proliferation
Caramoy, A., Ristau, T., Lechanteur, Y. T. E., Ersoy, L., Müller, S., Gelişken, F., Hoyng, C. B., Kirchhof, B., den Hollander, A. I., & Fauser, S. (2014) · Acta Ophthalmologica · doi:10.1111/aos.12437 · Cited by 25
“RAP differs from typical CNV in natural course showing a rapid and severe vision loss (Viola et al. 2009) and good response to treatment but high recurrence rates (Stoffelns et al.”
BackgroundYang, Q., Cai, Y., Ma, Q., Xiong, A., Xu, P., Zhang, Z., Xu, J., Zhou, Y., Liu, Z., Zhao, D., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adk3868 · Cited by 24
Clinical Applications of Diagnostic Indocyanine Green Angiography
Staurenghi, G., Bottoni, F. G., & Giani, A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00002-3 · Cited by 21
Self-citationKim, Y., Park, S. J., Woo, S. J., & Park, K. H. (2016) · Retina · doi:10.1097/iae.0000000000000952 · Cited by 19
“It has a high vasogenic potential and the prognosis differs from other types of neovascular age-related macular degeneration.(2) It is not uncommon in White patients,(3) whereas it has been less frequently reported in Asian populations.”
BackgroundExudative AMD subtypes and eligibility for treatment with ranibizumab
George, S. M., Cooke, C. A., & Chakravarthy, U. (2009) · Eye · doi:10.1038/eye.2009.301 · Cited by 17
Park, Y. G., & Roh, Y. (2015) · BMC Ophthalmology · doi:10.1186/s12886-015-0172-2 · Cited by 17
“Retinal angiomatous proliferation (RAP) has been described as a variant of exudative age-related macular degeneration (AMD).”
BackgroundInfluentialInvernizzi, A., Teo, K. Y. C., Nguyen, V., Daniell, M. D., Squirrell, D., Barthelmes, D., & Gillies, M. C. (2018) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2018-312944 · Cited by 16
Incidence and risk factors of massive subretinal hemorrhage in retinal angiomatous proliferation
Lee, J. H., Lee, M. Y., & Lee, W. K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186272 · Cited by 15
Marques, J. P., Laíns, I., Costa, M. A., Pires, I., Cachulo, M. L., Figueira, J., & da Silva, R. M. (2015) · Retina · doi:10.1097/iae.0000000000000619 · Cited by 16
Saito, M., Iida, T., & Kano, M. (2012) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-012-0215-7 · Cited by 14
Seidel, G., Werner, C., Weger, M., Steinbrugger, I., & Haas, A. (2013) · Acta Ophthalmologica · doi:10.1111/aos.12111 · Cited by 13
Phase-Resolved Doppler Optical Coherence Tomographic Features in Retinal Angiomatous Proliferation
Amarakoon, S., de Jong, J. H., Braaf, B., Yzer, S., Missotten, T., van Velthoven, M. E. J., & de Boer, J. F. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.07.026 · Cited by 13
Forte, P., Pâques, M., Cattaneo, J., Dupas, B., Castro‐Farías, D., Girmens, J., Siab, M., Biagini, F., Nicolò, M., Eandi, C. M., et al. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.01.007 · Cited by 12
Bochicchio, S., Xhepa, A., Secondi, R., Acquistapace, A., Oldani, M., Cigada, M., Giani, A., & Staurenghi, G. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.08.003 · Cited by 12
Self-citationBrowning, A. C., O’Brien, J. M., Vieira, R., Gupta, R., & Nenova, K. (2019) · Ophthalmologica · doi:10.1159/000500203 · Cited by 13
Multimodal Evaluation of the Fellow Eye of Patients with Retinal Angiomatous Proliferation
Martins, A., Farinha, C., Raimundo, M., Lopes, M., Santos, A. R., Melo, P., Marques, M., Marques, J. P., Barreto, P., Cachulo, M. L., et al. (2017) · Ophthalmic Research · doi:10.1159/000481262 · Cited by 11
Najeeb, B. H., Deák, G. G., Schmidt-Erfurth, U. M., & Gerendas, B. S. (2021) · Acta Ophthalmologica · doi:10.1111/aos.14866 · Cited by 11
Fallico, M., Macchi, I., Maugeri, A., Favara, G., Barchitta, M., Lio, R. M. S., Agodi, A., Russo, A., Longo, A., Avitabile, T., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1141077 · Cited by 10
“(Viola et al., 2009).”
InfluentialShort-term efficacy of intravitreal Aflibercept injections for retinal angiomatous proliferation
Chou, H., Wu, W., Wang, N., Chuang, L., Chen, K., & Lai, C. (2017) · BMC Ophthalmology · doi:10.1186/s12886-017-0497-0 · Cited by 10
Treatment Effects in Retinal Angiomatous Proliferation Imaged with OCT Angiography
de Jong, J. H., Braaf, B., Amarakoon, S., Gräfe, M. G. O., Yzer, S., Vermeer, K. A., Missotten, T., de Boer, J. F., & van Velthoven, M. E. J. (2018) · Ophthalmologica · doi:10.1159/000491798 · Cited by 9
Hayashi, T., Ohkuma, Y., Sakai, T., Watanabe, A., Yamada, H., Akahori, M., Itabashi, T., Iwata, T., Noda, T., & Tsuneoka, H. (2013) · Clinical ophthalmology · doi:10.2147/opth.s56483 · Cited by 12
Maruyama-Inoue, M., Sato, S., Yamane, S., & Kadonosono, K. (2019) · Clinical ophthalmology · doi:10.2147/opth.s224319 · Cited by 9
Lommatzsch, A. P. (2010) · Der Ophthalmologe · doi:10.1007/s00347-010-2143-6 · Cited by 8
Maier, M. M., Perz, C., Bockmaier, J., Feucht, N., & Lohmann, C. (2012) · Der Ophthalmologe · doi:10.1007/s00347-012-2732-7 · Cited by 8
Current Perspectives on Type 3 Macular Neovascularization due to Age-Related Macular Degeneration
Clemens, C. R., Eter, N., & Alten, F. (2024) · Ophthalmologica · doi:10.1159/000536278 · Cited by 7
“The natural history of MNV3 is characterized by exudative maculopathy, leading to severe and rapid visual loss in a large proportion of patients [79].”
BackgroundBonyadi, M. H. J., Yaseri, M., Bonyadi, M., & Soheilian, M. (2016) · International Ophthalmology · doi:10.1007/s10792-016-0413-2 · Cited by 7
Viola, F., Mapelli, C., Villani, E., Carducci, F. T., Vezzola, D., & Ratiglia, R. (2010) · Eye · doi:10.1038/eye.2010.33 · Cited by 6
Self-citationRetinale angiomatöse Proliferationen mit assoziierter Pigmentepithelabhebung
Lommatzsch, A. P., Heimes, B., Gutfleisch, M., Spital, G., Dietzel, M., & Pauleikhoff, D. (2010) · Der Ophthalmologe · doi:10.1007/s00347-010-2221-9 · Cited by 6
Saito, M., Iida, Kano, & Itagaki (2012) · Clinical ophthalmology · doi:10.2147/opth.s36333 · Cited by 6
Malamos, P., Tservakis, I., Kanakis, M. G., Koutsiouki, C., Kiskira, E., Mylonas, G., Lakoumentas, J., & Georgalas, I. (2018) · Ophthalmologica · doi:10.1159/000487610 · Cited by 6
Evaluating Retinal Angiomatous Proliferation With Optical Coherence Tomography Angiography
Mao, J., Cheng, D., Lin, J., Chen, Y., Lv, Z., & Shen, L. (2020) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20200228-02 · Cited by 6
Huang, Y.-Y., Lo, W.-J., Chang, H., Chou, Y.-B., & Lin, T. (2022) · Ophthalmology and Therapy · doi:10.1007/s40123-022-00521-y · Cited by 5
Najeeb, B. H., & Schmidt-Erfurth, U. M. (2024) · Eye · doi:10.1038/s41433-024-03034-z · Cited by 5
Faes, L., Bijon, J., Bacci, T., & Freund, K. B. (2024) · Eye · doi:10.1038/s41433-024-03343-3 · Cited by 6
“Untreated type 3 MNV carries a poor visual prognosis, as it can be accompanied by persistent retinal exudation culminating in subretinal fibrosis and atrophy [74].”
EPIMACULAR BRACHYTHERAPY FOR THE TREATMENT OF RETINAL ANGIOMATOUS PROLIFERATION
Petrarca, R., Nau, J. A., Dugel, P. U., & Jackson, T. L. (2011) · Retinal Cases & Brief Reports · doi:10.1097/icb.0b013e31823c12a3 · Cited by 5
Najeeb, B. H., Gerendas, B. S., Sacu, S., Leingang, O., Deák, G. G., & Schmidt-Erfurth, U. M. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.12.37 · Cited by 4
“5,43 Western Europe had the highest prevalence of MNV3 worldwide.”
Sepetis, A. E., Barbara, R., Frisina, R., Farag, M. H., & Salvo, G. D. (2024) · Eye · doi:10.1038/s41433-023-02918-w · Cited by 3
“Prior to the anti-VEGF era, RAP lesions were consider to be refractory to photodynamic therapy and/or intravitreal triamcinolone acetonide injections and progression to poor vision was common and rapid [9].”
Clinical Applications of Diagnostic Indocyanine Green Angiography
Staurenghi, G., Bottoni, F. G., & Giani, A. (2013) · Elsevier eBooks · doi:10.1016/b978-0-323-26254-5.00002-8 · Cited by 3
Self-citationMarques, M. F., Marques, J. P., Gil, J., Costa, J. C., Almeida, E., Cachulo, M. L., Pires, I., Figueira, J., & da Silva, R. M. (2015) · Ophthalmic Research · doi:10.1159/000441797 · Cited by 3
Short‐term progression of wet AMD and correlation with 1‐year treatment results
Munk, M. R., Kiss, C., Sulzbacher, F., Eisenkoelbl, S., Sacu, S., Kalcher, K., Jampol, L. M., & Schmidt-Erfurth, U. M. (2012) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2011.02353.x · Cited by 2
“In the era before anti-VEGF therapies, many studies examined the natural history and progression of neovascular AMD (Klein et al. 1997; Shah & Del Priore 2007; Wang et al. 2007; Wong et al. 2008; Viola et al. 2009) All these studies focused on long-term progression of nAMD and described the natural history of VA loss…”
BackgroundOptical Coherence Tomography of the Outer Retinal Layers
Koh, A. (2014) · ESASO course series · doi:10.1159/000355870 · Cited by 2
Response of a single-dose intravitreal brolucizumab in type 3 macular neovascularization
Chakraborty, S., & Sheth, J. U. (2023) · Indian Journal of Ophthalmology - Case Reports · doi:10.4103/ijo.ijo_2957_22 · Cited by 1
Long term follow up of patients with MNV3 treated with intra-vitreal Aflibercept
Browning, A. C., Grinton, M. E., Quinn, S. A., Jain, T., Manikavasagar, V., & Aftab, A. M. (2024) · European Journal of Ophthalmology · doi:10.1177/11206721241229912 · Cited by 1
“10 It is thought to comprise between 15 – 20% of cases of newly diagnosed nAMD in Caucasians.”
Yoon, E. G., Nam, K. T., Choi, M., Choi, K.-E., & Yun, C. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.5.10 · Cited by 1
“The pathogenesis of type 3 MNV in neovascular AMD is not yet fully understood, but it is more frequent in eyes with soft drusen and SDDs. 8,9,13,29,30 29–32 This hypothesis is supported by a study that measured higher VEGF-A levels in the aqueous humor in eyes with type 3 MNV compared to eyes with…”
Gillies, M. C., Nguyen, C. L., Nguyen, V., Daïen, V., Cohn, A., Banerjee, G., & Arnold, J. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.10.031 · Cited by 1
Stage 1 Type 3 Neovascularization With Choroidal Dilation Unresponsive to Anti-VEGF Treatment
Vujosevic, S., Martini, F., & Midena, E. (2016) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20161004-10
Retinal Pigment Epithelial Detachment in Retinal Angiomatous Proliferation
Gamulescu, M. (2017) · Springer eBooks · doi:10.1007/978-3-319-56133-2_5
Anti-VEGF en las lesiones polipoideas y la proliferación angiomatosa de la retina
Rodríguez, M. F., & Irazazábal, F. G.-U. D. (2010) · Elsevier eBooks · doi:10.1016/b978-84-8086-706-1.50011-0
Metadata
- Authors
- VIOLA, F., MASSACESI, A., ORZALESI, N., RATIGLIA, R., & STAURENGHI, G.
- Affiliations
- University of Milan (IT)
- Ospedale San Giuseppe (IT)
- Corresponding author
- VIOLA, FRANCESCO
- RATIGLIA, ROBERTO
- Venue
- Retina
- Published
- 2009-06
- Volume
- 29
- Issue
- 6
- Pages
- 732-739
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W1990850867
- Cited by
- 79
- References
- 22
- Citations by year
- 2025: 3 · 2024: 6 · 2023: 2 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 3 · 2018: 5 · 2017: 7 · 2016: 6 · 2015: 7 · 2014: 4 · 2013: 7 · 2012: 7
- FWCI
- 6.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Retina (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- retinal angiomatous proliferation, neovascular age-related macular degeneration, natural history (disease), visual acuity loss, visual prognosis, subretinal fibrosis
- MeSH terms
- Aged, Aged, 80 and over, Arteriovenous Anastomosis, Blindness, Choroid, Coloring Agents, Female, Fibrosis, Fluorescein Angiography, Humans, Indocyanine Green, Macular Degeneration, Male, Middle Aged, Ophthalmoscopy, Retina, Retinal Vessels, Visual Acuity, Retinal Neovascularization, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.